The Dupilumab studies were 16 weeks long. This is a very short time to truly evaluate a drug in this very difficult and prolonged skin problem. In addition, there were no objective comments on rash, redness, skin oozing, edema and pain. There are no long term follow ups reported.
Links to patient comments after the study was completed, I have found to be mostly negative. Many patients are still using steroids. Was it worth being in the study?
Stop the steroids.
See the links to patient comments below:
Finally, both Forbes and the New York Times published editorials about the drug. They cited the cost at $37,000 per year. They made no comments about the efficacy of the drug. This is outrageous.